Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

56.66
-1.8000-3.08%
Post-market: 56.660.00000.00%16:10 EDT
Volume:550.44K
Turnover:31.44M
Market Cap:2.63B
PE:15.52
High:58.89
Open:58.10
Low:56.59
Close:58.46
52wk High:87.32
52wk Low:47.32
Shares:46.47M
Float Shares:46.47M
Volume Ratio:0.63
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.65
EPS(LYR):3.31
ROE:19.30%
ROA:6.45%
PB:2.89
PE(LYR):17.12

Loading ...

Haemonetics Cut to Hold From Buy by Needham

Dow Jones
·
Dec 15, 2025

Haemonetics Corp : Needham Cuts to Hold From Buy

THOMSON REUTERS
·
Dec 15, 2025

Haemonetics Is Maintained at Neutral by JP Morgan

Dow Jones
·
Dec 13, 2025

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

GlobeNewswire
·
Dec 12, 2025

Haemonetics Cut to Neutral From Buy by Citigroup

Dow Jones
·
Dec 11, 2025

Citigroup Downgrades Haemonetics to Neutral From Buy, Adjusts PT to $88 From $77

MT Newswires Live
·
Dec 11, 2025

Haemonetics Corp : Bofa Global Research Raises Price Objective to $90 From $75

THOMSON REUTERS
·
Dec 08, 2025

Haemonetics (HAE): Reassessing Valuation After a 55% Three-Month Share Price Surge

Simply Wall St.
·
Dec 08, 2025

Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit

GlobeNewswire
·
Dec 08, 2025

Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says

MT Newswires Live
·
Dec 05, 2025

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga_recent_news
·
Dec 03, 2025

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

GlobeNewswire
·
Dec 03, 2025

How New Pediatric APeX-P Data at BioCryst (BCRX) Has Changed Its Investment Story

Simply Wall St.
·
Dec 02, 2025

Did Analyst Optimism on PHVS Pipeline Outweigh Continued Losses in Pharvaris’ Latest Results?

Simply Wall St.
·
Nov 25, 2025

Haemonetics Price Target Maintained With a $88.00/Share by BTIG

Dow Jones
·
Nov 21, 2025

Haemonetics (HAE): Assessing Valuation After Profit Beat and Completion of Major Buyback

Simply Wall St.
·
Nov 14, 2025

Director Makes Bold Move with Major Haemonetics Stock Purchase

TIPRANKS
·
Nov 13, 2025

Director Mark W. Kroll Reports Acquisition of Haemonetics Corporation Common Shares

Reuters
·
Nov 13, 2025

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 12, 2025

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

GlobeNewswire
·
Nov 10, 2025